Drugs / ORKA-001
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06698939 | Dec 2024 → Mar 2026 | — | Oruka Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07449702 | Feb 2026 → May 2030 expected | psoriasis | Oruka Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07290569 | Dec 2025 → Jun 2027 expected | psoriasis | Oruka Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07090330 | Jul 2025 → Mar 2026 overdue | psoriasis | Oruka Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-05-06 | Halozyme Therapeutics | Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology halozyme.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORKA-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06698939 ↗ |
| Route | Subcutaneous | “administered by SC injection” NCT06698939 ↗ |